This week, we talk to a company in Lund, Asgard Therapeutics, and its co-founder and CEO Cristiana Pires, about in vivo direct cell reprogramming for cancer immunotherapy, and we chat about clinical diagnostics with Meriem Sefta, CEO of Waiv.
Times:
03:17 Asgard Therapeutics
32:43 Waiv
Asgard Therapeutics
Asgard Therapeutics is a biotech pioneering in vivo direct cell reprogramming for cancer immunotherapy.
Asgard is using an innovative approach to force tumour cells to present their antigens to the immune system, thereby triggering personalised anti-tumour immune responses.
The team presented advanced preclinical data on lead asset AT-108 at ASGCT earlier this year, showing that, when used as a monotherapy, AT-108 doubled median survival.
When used in combination with immune checkpoint blockade, AT-108 demonstrated strong anti-tumour activity, including significantly extending survival and achieving complete tumour regressions.
AI-powered diagnostics
Waiv is a precision oncology company that spun out of Owkin last year to focus exclusively on AI-powered diagnostics.
Waiv uses its AI to analyse routine pathology images, helping clinicians identify patients who may benefit from further molecular testing and ultimately the right treatment, without requiring additional tissue needed by requesting additional painful patient biopsies or changes to clinical workflow.
Its tests accelerate biomarker discovery and detection, outcome prediction, and treatment-response assessment across oncology.
Built on over seven years of validated medical-AI innovation and one of Europe’s largest multi-institutional data networks, Waiv delivers precise, accurate, and fast analyses that support treatment decisions. It collaborates with global pharmaceutical companies, research institutions, diagnostic organisations and healthcare systems to bring scalable precision medicine to patients worldwide.
To get in touch with guest suggestions, or to sponsor or advertise on the podcast, please email jim@deeptechdigest.com
